In 226 patients with refractory cancer pain randomised to bolus-only or bolus plus continuous infusion hydromorphone PCIA, 72-hour pain relief was 89.4% vs 94.2%; non-inferiority of bolus-only was not shown. PCIA-related adverse events were comparable.
RCTn = 226
Yan et al. Bolus-only versus bolus plus continuous infusion hydromorphone for refractory cancer pain: a prospective, multicenter, randomized noninferiority trial